RE:FDA approval
CONCORDIA HEALTHCARE GETS FDA APPROVAL FOR NEW PHOTOFRIN LASER LESS THAN 1 MINUTE AGO BY MT NEWSWIRES Page 1Page 2Page 3Page 4Page 5Page 6Page 7Page 8Page 9Page 10Page 11Page 12Page 13Page 14Page 15 07:19 AM EDT, 06/30/2016 (MT Newswires) -- Concordia Healthcare (CXRX), a specialty pharmaceutical company, said Thursday that the U.S. Food and Drug Administration has approved the company's premarket approval application for its new Photofrin 630 PDT Laser. Photodynamic therapy with Photofrin is Concordia's light-based cancer treatment that combines a photosensitizing drug called Photofrin (porfimer sodium) with a specific type of light administered by a laser to attack cancer cells. The newly approved laser, which is designed for use with Photofrin to treat esophageal cancer, Barrett's Esophagus and non-small cell lung cancer, has been re-engineered with technological advancements in laser design. These advancements include new controls and peripheral systems while maintaining the same specifications with minimal changes to the treatment procedures. The company is also evaluating Photofrin's safety and efficacy as a potential treatment for cholangiocarcinoma, or bile duct cancer in a phase 3 clinical trial. Price: 20.58, Change: , Percent Change: